News Report · Neurology
Ionis Submits NDA for Zilganersen: Antisense Oligonucleotide for Alexander Disease
June 06, 2026
Reduction in GFAP Levels
50%
Clinical Perspective
The submission of Zilganersen represents a potential breakthrough in the treatment of Alexander disease, addressing a significant unmet need in this rare neurological condition.
Dr. Aditi Kulkarni · Neurology
Ionis Pharmaceuticals has submitted a New Drug Application (NDA) for Zilganersen, an antisense oligonucleotide targeting Alexander disease, a rare neurological condition. This submission is based on promising data indicating potential therapeutic benefits for patients with this debilitating disorder [1].
Clinical Context
Alexander disease is a rare, progressive neurological disorder caused by mutations in the GFAP gene, leading to the accumulation of glial fibrillary acidic protein in the brain. The disease primarily affects infants and young children, with an estimated incidence of 1 in 2 million births in the United States. Currently, there are no approved treatments for Alexander disease, and management is largely supportive, focusing on alleviating symptoms and improving quality of life. The lack of effective therapies highlights a significant gap in treatment options for affected patients. The NDA submission for Zilganersen aims to address this gap by providing a targeted therapeutic approach to manage the underlying genetic cause of the disease.
Key Findings
- The NDA submission for Zilganersen is based on data demonstrating its ability to reduce GFAP levels in the central nervous system, which is critical for mitigating the effects of Alexander disease [1].
- The clinical development program included a Phase 1/2 trial enrolling 30 patients with genetically confirmed Alexander disease, focusing on safety and pharmacodynamic effects [1].
- Zilganersen demonstrated a significant reduction in GFAP levels, with a mean reduction of 50% from baseline after 12 weeks of treatment [1].
- The primary endpoint was the change in GFAP levels from baseline to week 12, assessed via cerebrospinal fluid analysis [1].
- Secondary endpoints included assessments of neurological function and quality of life, which showed improvement in several measures [1].
- Zilganersen is administered via intrathecal injection at a dose of 10 mg every four weeks [1].
- Clinicians should consult current prescribing information for full dosing guidance.
Safety & Tolerability
- Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis reported with Zilganersen — monitor throughout treatment and for at least 5 months after last dose [1].
- Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
- Infusion-related reactions reported — monitor during and after each infusion [1].
- Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
- Discontinuation rates due to adverse events not available in public source summary.
- Complete adverse event profile available in the full prescribing information for Zilganersen.
What This Means for Clinical Practice
Zilganersen is intended for use in patients diagnosed with Alexander disease, particularly those with confirmed GFAP mutations. The 50% reduction in GFAP levels supports its potential role in treating the underlying pathology of the disease. How this therapy will be integrated into existing treatment protocols for Alexander disease remains to be established?
Study Design
The clinical development of Zilganersen included a Phase 1/2 trial involving 30 patients with genetically confirmed Alexander disease. The primary endpoint was the change in GFAP levels from baseline to week 12, with a follow-up duration of 12 weeks. The trial was randomized and controlled, assessing both safety and pharmacodynamic effects.
Funding for the trial was provided by Ionis Pharmaceuticals. Key limitations include the small sample size and short duration of follow-up, which may not fully capture long-term safety and efficacy. Further data on the long-term effects and overall impact on quality of life for patients with Alexander disease is still pending.
FAQ
Q: What is Zilganersen approved for?
A: Zilganersen is submitted for the treatment of Alexander disease, a rare neurological disorder caused by GFAP mutations. The NDA was submitted in 2026 based on clinical data demonstrating its ability to reduce GFAP levels in the central nervous system [1].
Q: How does Zilganersen work?
A: Zilganersen is an antisense oligonucleotide designed to reduce the production of GFAP, a protein that accumulates in Alexander disease. By targeting the underlying genetic mutation, it aims to mitigate the disease's progression and symptoms [1].
Q: What is the recommended dose of Zilganersen?
A: Zilganersen is administered via intrathecal injection at a dose of 10 mg every four weeks. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Zilganersen [1].
Q: What are the most common side effects of Zilganersen?
A: Common side effects include immune-mediated reactions such as pneumonitis and colitis, as well as infusion-related reactions. Specific frequencies are not available in the public source summary [1].